Novavax to begin Ebola vaccine trials By: MarketMinute.com Stock News October 27, 2014 at 17:34 PM EDT Novavax Inc. (Nasdaq: NVAX) will begin a Phase 1 Ebola vaccine clinical trial in December. Shares of the biopharmaceutical climbed 67 cents to close at $5.80. Related Stocks: Novavax Inc